The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape
Source: Streetwise Reports (05/22/2026)

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
Source: Richard Ryan (05/21/2026)

BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Source: Streetwise Reports (05/20/2026)

Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Source: Dr. Yun Zhong (05/20/2026)

Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.

Biotech Co. Unveils Scalable AI Voice Biomarker Platform
Source: Streetwise Reports (05/13/2026)

MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) CEO says proprietary AI voice analytics could transform impairment screening across zero-tolerance industries.